P2RX7 and basal cell carcinoma: Related to the potential of the anti‐P2X7 mAb mediating CDC in vivo, a phase 1 clinical trial using topical treatment of a polyclonal antibody to non‐functional P2X7 (BIL010t) can reduce the size of primary basal cell carcinoma lesions in 65% of patients [31].